Inquire About a Product| Product: | Ranolazine | ||||
|---|---|---|---|---|---|
| Catalog Number: | 18758 | ||||
| CAS Number: | 95635-55-5 | ||||
| Pricing: |
|
||||
| Formula: | C24H33N3O4 | ||||
| Molecular Weight: | 427.54 | ||||
| Structure: |
|
||||
| Appearance: | White solid | ||||
| Category: | Unlabeled Reference Standards | ||||
| Stability: | Stable under recommended storage conditions. | ||||
| Storage: |
Keep container tightly closed in a dry and well-ventilated place. Desiccate at room temperature |
||||
| Transportation: |
Non-hazardous for transport |
||||
| Literature References: |
McCormack, J.G., et al. 1998. Gen. Pharmacol. 30: 639-645. PMID: 9559312; Schofield, R.S. and Hill, J.A. 2002. Expert Opin Investig Drugs. 11: 117-123. PMID: 11772326; Chaitman, B.R., et al. 2004. J. Am. Coll. Cardiol. 43: 1375-1382. PMID: 15093870; Michels, G., et al. 2010. Dtsch. Med. Wochenschr. 135: 2037-2040. PMID: 20925013; Mito, M.S., et al. 2010. Mol. Cell. Biochem. 345: 35-44. PMID: 20680408 |
||||
| MSDS: | |||||
| Description: |
Ranolazine is an anti-ischemic which inhibits late sodium current that results in a reduction of Na+ dependent Ca2+ overload. Studies indicate that ATP production is shifted towards glucose oxidation by Ranolazine. This is due to the fact that more oxygen is required to phosphorylate the same amount of ATP during fatty acid oxidation than carbohydrate oxidation. These studies indicate that Ranolazine also inhibits oxygen consumption and ketogenesis by fatty acids in liver cells |